We are live on ! Find out more
BIOTW

Biotech Acquisition Company Warrant
BIOTW

Delisted

BIOTW was delisted on the 2nd of February, 2023.

Back to rankings

48 hedge funds and large institutions have $4.21M invested in Biotech Acquisition Company Warrant in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 4

8% less funds holding

Funds holding: 52 → 48 (-4)

17% less capital invested

Capital invested by funds: $5.06M → $4.21M (-$846K)

44% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 9

Holders
48
Holders Change
-4
Holders Change %
-7.69%
% of All Funds
0.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
4
Closed
9
Calls
$5.72M
Puts
–
Net Calls
+$5.72M
Net Calls Change
-$26K

Top Buyers

Rank Fund Capital Flow
1
HIM
HGC Investment Management
Ontario, Canada
+$254K
2
RA
Ramius Advisors
New York
+$117K
3
PAMP
Polar Asset Management Partners
Ontario, Canada
+$87.8K
4
SCM
Shaolin Capital Management
Florida
+$20.7K
5
BFM
Boothbay Fund Management
New York
+$11.9K

Top Sellers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
-$94.8K
2
Citadel Advisors
Citadel Advisors
Florida
-$87.9K
3
SRCM
Sage Rock Capital Management
New York
-$69K
4
MF
Magnetar Financial
Illinois
-$49K
5
PC
Periscope Capital
Ontario, Canada
-$40K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$2.01M – – –
BFM
2
Boothbay Fund Management
New York
$880K +$11.9K +57,641 +185%
LP
3
LMR Partners
United Kingdom
$495K – – –
HIM
4
HGC Investment Management
Ontario, Canada
$403K +$254K +1,227,583 +101%
PAMP
5
Polar Asset Management Partners
Ontario, Canada
$56K +$87.8K +425,000 +217%
RA
6
Ramius Advisors
New York
$51K +$117K +567,986 New
CCP
7
Corbin Capital Partners
New York
$42K – – –
AC
8
Aristeia Capital
Connecticut
$39K -$94.8K -458,971 -43%
KCM
9
Kingstown Capital Management
New York
$27K – – –
QGA
10
Q Global Advisors
Texas
$27K – – –
SCM
11
Shaolin Capital Management
Florida
$18K +$20.7K +99,977 +100%
LA
12
Linden Advisors
New York
$16K – – –
MI
13
MMCAP International
Cayman Islands
$13K – – –
TCM
14
Tenor Capital Management
New York
$13K – – –
ACM
15
Atalaya Capital Management
New York
$11K – – –
SC
16
Sculptor Capital
New York
$10K – – –
ACA
17
Arena Capital Advisors
California
$9K – – –
DKCM
18
Davidson Kempner Capital Management
New York
$6K – – –
TI
19
Telemetry Investments
New York
$6K – – –
Walleye Capital
20
Walleye Capital
New York
$6K +$3.71K +17,954 +38%
AC
21
Antara Capital
New York
$5K – – –
CP
22
Centerbridge Partners
New York
$5K – – –
WA
23
Whitebox Advisors
Minnesota
$5K – – –
Jane Street
24
Jane Street
New York
$5K +$70 +338 +0.6%
CCM
25
Context Capital Management
California
$4K -$10.3K -50,000 -51%
1
2 3

BIOTW Hedge Fund Activity: Q2 2022 in Review

48 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q2 2022, worth a combined $4.21M — down 17% from $5.06M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of BIOTW and 5 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 10 added.

The largest buyer was HGC Investment Management, adding an estimated $254K. The largest seller was Aristeia Capital, cutting an estimated $94.8K.

  • 48 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q2 2022, down from 52 in Q1 2022.
  • Funds reported $4.21M of Biotech Acquisition Company Warrant stock for Q2 2022, down 17% quarter-over-quarter.
  • 5 funds opened new Biotech Acquisition Company Warrant positions in Q2 2022 and 9 closed out, a net change of -4 holders.
  • The largest Biotech Acquisition Company Warrant buyer in Q2 2022 was HGC Investment Management, an estimated $254K added.
  • The largest Biotech Acquisition Company Warrant seller in Q2 2022 was Aristeia Capital, an estimated $94.8K sold.

Based on aggregated 13F filings for Q2 2022.